Technology evaluation: PROSTVAC, Therion.
Therion Biologics is developing PROSTVAC, an immunotherapeutic vaccine that targets prostate-specific antigen, for the potential treatment of prostate cancer. In February 2000, phase II trials had commenced. By October 2001, the drug was undergoing four phase II trials.